Theravance Biopharma, Inc.
TBPHDrugs in Pipeline
10
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ampreloxetine
Symptomatic Neurogenic Orthostatic Hypotension
TD-1792
Staphylococcal Skin Infection
Velusetrag
Gastroparesis
TD-0903
Acute Lung Injury (ALI) Associated With COVID-19
TD-1211
Healthy
TD-8236
Asthma
TD-9855 Group 1
Fibromyalgia
velusetrag dose 1
Gastroparesis
TD-9855
Neurogenic Orthostatic Hypotension
400 microgrammes GSK961081
Pulmonary Disease, Chronic Obstructive
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ampreloxetine | Phase 3 | Symptomatic Neurogenic Orthostatic Hypotension | - | - |
TD-1792 | Phase 2 | Staphylococcal Skin Infection | - | - |
Velusetrag | Phase 2 | Gastroparesis | - | - |
TD-0903 | Phase 2 | Acute Lung Injury (ALI) Associated With COVID-19 | - | - |
TD-1211 | Phase 2 | Healthy | - | - |
TD-8236 | Phase 2 | Asthma | - | - |
TD-9855 Group 1 | Phase 2 | Fibromyalgia | - | - |
velusetrag dose 1 | Phase 2 | Gastroparesis | - | - |
TD-9855 | Phase 2 | Neurogenic Orthostatic Hypotension | - | - |
400 microgrammes GSK961081 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |